Physician profile
Scott Richard
NPI 1518002567
$84,275.94
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $758 · 2021: $18K · 2022: $621 · 2023: $67.16 · 2024: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $50,473.59 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $30,402.25 | 2019-2022 | |
| Glaxosmithkline, LLC. | $2,074.23 | 2021-2022 | |
| Dilon Technologies, INC. | $430.34 | 2024 | Hemoblast Bellows |
| Tesaro, INC. | $215.39 | 2019 | |
| Stryker Corporation | $173.86 | 2021 | |
| Biom'Up Sa | $164.65 | 2019 | |
| Myriad Genetic Laboratories, INC. | $96.21 | 2021 | |
| Coopersurgical, INC. | $70.59 | 2021 | |
| Eisai INC. | $67.16 | 2023 | |
| Baxter Healthcare | $65.21 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $27.94 | 2019 | |
| Ethicon US, LLC | $14.52 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Richard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.